Scientists track how experimental drug BI 1015550 breaks down in the body
NCT ID NCT04771286
First seen Dec 02, 2025
Summary
This early-phase study looked at how healthy men process and eliminate a single dose of the experimental drug BI 1015550. Six participants took a radioactive-labelled version of the drug so researchers could track its breakdown in urine and stool. The goal was to understand the drug's metabolism and how it leaves the body, which is essential for planning future studies in patients with lung conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON
Groningen, 9728 NZ, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1015550 (Nerandomilast)
What this could lead to
If successful, this study will help researchers understand how BI 1015550 is processed and eliminated by the body, guiding future trials for conditions like pulmonary fibrosis.
What could go wrong
This is a very early, small study in just 6 healthy men. It is designed to gather basic information, not to test if the drug works for any disease. Results may not apply to patients.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.